Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults
Submitted by
admin
on May 24, 2014 - 9:44am
Source:
Yahoo/Globe Newswire
News Tags:
Durata Therapeutics
Dalvance
MRSA
skin infection
Headline:
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults
Do Not Allow Advertisers to Use My Personal information
